Briefing
Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.
In 190 people with stage I to IIIB melanoma (1,578 samples), postoperative ctDNA measured with a tumor-informed 16-plex PCR sequencing assay was associated with shorter recurrence-free survival (HR 40.63).
- Design: Evidence level 2
- Assay: mPCR-NGS
Clinical Cancer ResearchPubMed 41632449DOI 10.1158/1078-0432.CCR-25-3643